Clinical trial budgets rarely fail because the original number was wrong. They fail because the assumptions underneath the number were never revisited as the study evolved — and by the time the gap becomes visible in a financial report, it is already too large to close quietly.
The overrun starts at protocol design, not at execution
The single biggest driver of budget overruns is protocol complexity added after the initial budget is set — an extra imaging visit, an additional biomarker sample, an amended inclusion criterion that slows enrollment. Each change is individually reasonable. Collectively, they can add 20-30% to operational cost without anyone deciding, at any single point, to spend that much more.
Enrollment delays cost more than they appear to on paper
A three-month enrollment delay does not just push the timeline by three months. It extends site payments, monitoring visits, IRT and central lab fees, and often triggers site retention costs to prevent coordinator turnover during the extended period. Budget models that treat timeline and cost as loosely linked, rather than tightly coupled, consistently underestimate the true cost of delay.
Site payment terms are a frequent, quiet source of drift
Milestone-based site payments look controlled on paper but are easy to lose track of in practice — particularly across a large site network with staggered activation dates. Payments triggered but not reconciled against actual milestone completion, or milestones renegotiated informally at the site level without updating the master budget, are a common and largely invisible source of overrun.
Vendor change orders accumulate faster than they get reviewed
Individually small change orders from a CRO, lab or imaging vendor are often approved quickly to avoid holding up study timelines. Reviewed individually, each looks justified. Reviewed quarterly against the original budget, the cumulative total is frequently the single largest unplanned cost category in a trial — and the one leadership is most surprised by at year-end.
Build a live budget-to-actual view, not a quarterly reconciliation
Waiting for a quarterly finance close to compare budget against actual spend means overruns are typically identified three to six months after the decisions that caused them. A lightweight, regularly updated budget tracker — even a well-maintained spreadsheet — that flags variance by category as it happens gives teams the chance to course-correct before a small drift becomes a funding conversation.
Where a structured tracker helps
Our Clinical Trial Budget & Payment Milestone Tracker gives clinical operations and finance teams a practical way to track site payments, vendor costs and budget variance against milestones as the study progresses, rather than discovering the gap at close-out.
For programmes needing a full budget and vendor cost review, our Clinical Trial Consulting service includes operational risk assessment that specifically covers budget exposure alongside timeline and quality risk.